BioFocus and Almac Collaborate to Offer Fluorescent Lifetime Assays

CRAIGAVON, Northern Ireland, March 28, 2011 - BioFocus and Almac have initiated a collaboration which will provide
BioFocus customers with compound screening and profiling services using
Almac's FLEXYTETM fluorescence lifetime (FLT) assays. FLT as a reading
modality offers a robust, antibody free, homogeneous assay platform which
enables the user to avoid interference from fluorescent compounds within a
screening library.

BioFocus has launched an FLT screening and profiling service utilising
the FLEXYTETM assay platform and now offer campaigns against targets
including proteases, phosphatases and kinases. The unique properties of FLT
have also been harnessed to open up access to previously inaccessible
epigenetics target classes. Several approaches can be taken using the
FLEXYTETM platform including fragment based screens and kinetic profiling.

"Being able to incorporate FLT in our service offering enables BioFocus
to provide clients an approach to screening and profiling that will unlock
significant potential within their drug discovery efforts," commented Dr Kate
Hilyard, VP Biological Sciences, BioFocus.

"We are delighted that BioFocus has chosen to add our FLEXYTETM platform
to their service offering. We feel that this will allow a broad range of drug
discovery groups access to the power of FLT," said Dr Stephen Barr, President
and Managing Director of Almac Sciences.

For media enquiries please contact: Tristan Jervis , Associate Director, DeFacto Communications, T.Jervis at Defacto.com , Tel: +44-2078-613019; Robert Grundy, PhD, Director Research Alliance, Almac Discovery Ltd, Robert.grundy at almacgroup.com , T: +44(0)28-3833-2200